Aptar Pharma, a leading provider of innovative drug delivery systems, in combination with Schott Glass and EMA Pharmaceuticals, has announced that it will launch Aptar Pharma QuickStart™ for injectable drug development at CPhI Worldwide 2018, in Madrid, Spain, October 9th.
Aptar Pharma QuickStart™ is a sterile, Ready-To-Use (RTU) drug development support kit designed specifically for research & development labs. A package complete with glass vials, elastomeric stoppers and caps, QuickStart™ provides everything needed for the small volume filling of high value formulations. Also included in the kit are all the quality and technical documentation required to verify the sterilization and compatibility (CCI) of components. Co-developed alongside Schott and EMA Pharmaceuticals, Aptar Pharma QuickStart™ is available to cater to different sizes and configurations of vials, stoppers and caps.
Aptar Pharma’s proven expertise in device development and formulation helps ensure that QuickStart™’s components satisfy all regulatory requirements, allowing users to access commercial scale quality at a development stage cost.
CPhI Worldwide, which takes place October 9-11, 2018 at IFEMA, Feria de Madrid, will welcome more than 45,000 pharma professionals, which provides a prime opportunity to demonstrate the value of Aptar Pharma QuickStart™ to prospective partners.
To read full Press Release, click here.